First, a bit of background on Moderna's RSV candidate. RSV generally causes cold-like symptoms, but the virus could be severe ...

HSBC Securities raised the price target for the Moderna Inc (NASDAQ:MRNA) stock from “a Hold” to “a Reduce”. The rating was released on February 26, 2024, according to finviz. The research report from ...

The biotech’s first product for something other than Covid doesn’t clearly perform any better than other shots on the market.

Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: ...

For now, the collaboration is not, in and of itself, a reason to buy Moderna stock. Nor is it a sign that you should go ...

Moderna said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC) advisers to recommend the company's ...

The U.S. drug regulator has pushed back its decision on Moderna's respiratory syncytial virus (RSV) vaccine due to ...

The FDA needs a few more weeks to decide the fate of Moderna's RSV vaccine, the company announced. A decision is now slated ...

Moderna is on the rise after the Food and Drug Administration delayed a decision on its RSV vaccine. But is MRNA stock, once again, a buy? Moderna's (MRNA) RSV vaccine, mRNA-1345's review timeline ...

U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by ...

The FDA has not informed Moderna of any issues related to the vaccine’s safety, efficacy or quality that would prevent its ...

(Bloomberg) -- Moderna Inc.’s pioneering Covid shot turned the company into a nearly $200 billion biotech giant and a public health hero. Its second vaccine, meant to prevent a common ...